Skip to main content
profile image
Matthew D. Sims, M.D., Ph.D.
Article
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial
JAMA (2022)
  • Stuart Cohen
  • Thomas J Louie
  • Matthew Sims, Beaumont Health
  • Elaine E L Wang
  • Asli Memisoglu
  • Barbara H McGovern
  • Lisa von Moltke
Link
Abstract
This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.
Keywords
  • Clostridioides difficile infection
Disciplines
Publication Date
November 22, 2022
DOI
10.1001/jama.2022.16476
Citation Information
Cohen SH, Louie TJ, Sims M, Wang EEL, Memisoglu A, McGovern BH, et al Extended follow-up of microbiome therapeutic ser-109 through 24 weeks for recurrent clostridioides difficile infection in a randomized clinical trial. JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476. PMID: 36260754.